Keywords
myoclonic epilepsy
Costa Rica
enfermedad de lafora
epilepsia mioclonica
Costa Rica
How to Cite
Abstract
A review of the main clinical, pathologic and genetic aspects of progressive myoclonus epilepsy Lafora type was undertaken. The diagnosed cases of this disorder in Costa Rica are mentioned.References
Acharya, J.N., P. Satishchandra & S.K. Shankar. 1995. Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 36: 429- 434.
Abbott, M.A., D.G. Wells & J.R. Fallon. 1999. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J. Neurosci. 19: 7300-7308.
Al Otaibi, S.F., B.A. Minassian, C.A. Ackerley, W.J. Logan & S. Weiss. 2003. Unusual presentation of Lafora’s disease. J. Child. Neurol. 18: 499-501.
}
Angenstein, F., W.T. Greenough & I.J. Weiler. 1998. Metabotropic glutamate receptor-initiated translocation of protein kinase p90rsk to polyribosomes: a possible factor regulating synaptic protein synthesis. Proc. Natl. Acad. Sci. USA 95: 15078-15083.
Baumann, R.J., S.A. Kocoshis & S. Wilson. 1983. Lafora disease: liver histopathology in presymptomatic children. Ann. Neurol. 4: 86-89.
Berkovic S.F., J. Cochius, E. Andermann & F. Andermann. 1993. Progressive myoclonus epilepsies: clinical and genetic aspects. Epilepsia 34: S19-30.
Broadwell, R.D. & A.M. Cataldo. 1983. The neuronal endoplasmic reticulum: its cytochemistry and contribution to the endomembrane system. I. Cell bodies and dendrites. J. Histochem. Cytochem. 31: 1077-1088.
Broadwell, R.D. & A.M. Cataldo. 1984. The neuronal endoplasmic reticulum: its cytochemistry and contribution to the endomembrane system. II. Axons and terminals. J. Comp. Neurol. 230: 231-248.
Busard, B.L., W.O. Renier, F.J. Gabreels, H.H. Jasper, U.J. van Haelst & J.L. Stooff. 1986. Lafora’s disease: comparison of inclusion bodies in skin and in brain. Arch. Neurol. 43: 296-299.
Busard, H.L., W.O. Renier, F.J. Gabreels, H.H. Jasper, J.L. Slooff, A.J. Jansen & U.J. van Haelst. 1987. Lafora disease: a quantitative morphological and biochemical study of the cerebral cortex. Clin. Neuropathol. 6: 1-6.
Busard, H.L., A.A. Gobreels-Festen, W.U. Renih, F.J. Gabreels & A.M. Stadhouders. 1987. Axila skin biopsy: a reliable test for diagnosis of Lafora’s disease. Ann. Neurol. 21: 599-601.
Carpenter, S., G. Karpati, F. Andermann, J.C. Jacob & E. Andermann. 1974. Lafora’s disease: Peroxisomal storage in skeletal muscle. Neurology 24: 531-538.
Carpenter, S. & G. Karpati. 1981. Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy. Neurology 31: 1564-1568.
Carpenter, S. & G. Karpati. 1981. Ultrastructural findings in Lafora disease. Ann. Neurol. 10: 63-64.
Cavanagh, J.B. 1999. Corpora amylacea and the family of polyglucosan diseases. Brain Res. Rev. 29: 265-295.
Chamlian, A. L., Benkoel, D. Minko, T. Njee & J.M. Gulian. 1989. Ultrastructural heterogeneity of glycogen in human liver. Liver 9: 346-350.
Chan, E.M., D.E. Bulman, A.D. Paterson, J. Turnbull, E. Andermann, F. Andermann, G.A. Rouleau, A.V. Delgado- Escueta, S.W. Scherer & B.A. Minassian. 2003a. Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J. Med. Genet. 40: 671-675.
Chan, E.M., E.J. Young, L. Ianzano, I. Munteanu, X. Zhao, C.C. Christopoulos, G. Avanzini, M. Elia, C.A. Ackerley, N.J. Jovic, S. Bohlega, E. Andermann, G.A. Rouleau, A.V. Delgado-Escueta, B.A. Minassian & S.W. Scherer. 2003b. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 35: 125-127.
Chan, E.M., C.A. Ackerley, H. Lohi, L. Ianzano, M.A. Cortez, P. Shannon, S.W. Scherer & B.A. Minassian. 2004a. Laforin preferentially binds to neurotoxic stach-like polyglucosans, which form in its absence
in progressive myoclonus epilepsy. Hum. Molec. Genet. 13: 1117-1129.
Chan, E.M., S. Omer, M. Ahmed, L.R. Bridges, C. Bennett, S.W. Scherer & B.A. Minassian. 2004b. Progressive myoclonus epilepsy with polyglucosans (Lafora disease). Evidence for a third locus. Neurology 63: 565-567.
Chen, Y.T. & A. Burchel. 1995. Glycogen Storage Diseases. pp. 935-965. In C.R. Scriber, A.L. Beaudet, W.S. Sly & D. Valle (eds.). The metabolic and molecular bases of inherited disease. McGrau-Hill. New York.
Collins, G.H., R.R. Cowden & A.H. Nevis. 1968. Myoclonus epilepsy with Lafora bodies: an ultrastructural and cytochemical study. Arch. Neurol. 86: 239-254.
Denu, J.M., J.A. Stuckey, M.A. Saper & J.E. Dixon. 1996. Form and function in protein dephosphorilation. Cell 87: 361-364.
DiMauro, S., W. Trojaborg, P. Gambetti & L.P. Rowland. 1971. Binding of enzymes of glycogen metabolism to glycogen in skeletal muscle. Arch. Biochem. Biophys. 144: 413-422.
Drury, I., M. Blaivas, B.Abou-Khalil & A. Beydoun. 1993. Biopsy results in a kindred with Lafora disease. Arch. Neurol. 50: 102-105.
Federico, A., A. Cecio, G.A. Battini, J.C. Michalski, G. Strecker & G.C. Guazzi. 1980. Macular cherry-red spot and myoclonus síndrome: juvenile form of sialidosis. J. Neurol. Sci. 48: 157-169.
Freemont, P.S. 2000. RING for destruction? Curr. Biol. 27: R84-87.
Fernández-Sánchez, M.E., O. Criado-García, K.E. Heath, B. García-Fojeda, I. Medrano- Fernández , P. Gómez-Garre, P. Sanz , J.M. Serratosa & S. Rodríguez De Córdoba. 2003. Laforin, the dual phosphatase responsable for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein
phosphatase-1 that enhances glycogen accumulation. Hum. Mol. Genet. 12: 3161-3171.
Fong, N.M., T.C. Jensen, A.S. Shah, A.R. Parekh, Saltiel & M.J. Brady. 2000. Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism. J. Biol. Chem. 275: 35034-35039.
Fukuhara, N., S. Tokiguchi, K. Shirakawa & T. Tsubaki. 1980. Myoclonus epilepsy associated with raggedred fibers (mitochondrial abnormalities ):disease entity or a syndrome ? Light and electron microscopic studies of two cases and a review of the literature. J. Neurol. Sci. 47: 117-133.
Ganesh, S., K. Amano, AV. Delgado-Escueta & K. Yamakawa. 1999. Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A. Biochem. Biophys. Res. Commun. 257: 24-28.
Ganesh, S., K.L. Agarwala, K. Ueda, T. Akagi, K. Skoda, T. Usui, T. Hashikawa, H. Osada, A.V. Delgado-Escueta & K. Yamakawa. 2000. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet. 9: 2251-2261.
Ganesh, S., K.L. Agarwala, K. Amano, T. Suzuki, A.V. Delgado-Escueta & K. Yamakawa. 2001. Regional and developmental expression of Epm2a gene and its evolutionary conservation. Biochem. Biophys. Res. Comun. 283: 1046-1053.
Ganesh, S., A.V. Delgado-Escueta, T. Sakamoto, M.R. Avila, J. Machado-Salas, Y. Hoshil, T. Akagi, H. Gomi, T. Suzuki, K. Amano, K.L. Agarwala, Y. Hasegawa, D.S. Bai, T. Ishihara, T. Hashikawa, S. Itohara,
E.M. Cornford, H. Niki & K. Yamakawa. 2002a. Targeted disruption of the Epm2a gene causes formation
of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 11: 1251-1262.
Ganesh, S., A.V. Delgado-Escueta, T. Suzuki, S. Francheschetti, C. Rigio, G. Avanzini, A. Rabinowicz, S. Bohlega, J. Bailey, M.E. Alonso, A. Rasmussen, A.E. Thomson, A. Ochoa, A.J. Prado, M.T. Medina & K.
Yamakawa. Genotype-phenotype correlations for EPM2A mutations in Lafora’s progressive myoclonus
epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. 2002b. Hum. Mol. Genet. 11: 1263-1271.
Ganesh, S., T. Suzuki & K. Yamakawa. 2002c. Alternative splicing modulates subcellular localization of laforin. Biochem. Biophys. Res. Commun. 291: 1134-1137.
Ganesh, S., N. Tsurutani, T. Suzuki, K. Ueda, K.L. Argawala, H. Osada, A.V. Delgado-Escueta & K. Yamakawa. 2003. The Lafora disease gene product laforin interacts with HIRIP5 phylogenetically conserved protein containing NifU-like domain. Hum. Mol. Genet. 12: 2359-2368.
Ganesh, S., N. Tsurutani, T. Suzuki, Y. Hoshii, T. Ishihara, A.V. Delgado-Escueta & K. Yamakawa. 2004. The carbohydrate binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem. Biophys. Res. Commun. 313: 1101-1109.
Gómez-Garre, P., Y. De Sanz, & J.M. Serratosa. 2000. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. Eur. J. Hum.Genet. 8: 946-54
Hafen, E. 1998. Kinases and phosphatases: a marriage is consummated. Science 280: 1212-1213.
Harriman, D.G. & J.H. Millar.1955. Progressive familial myoclonic epilepsy in three families: its clinical features and pathological basis. Brain 78: 325-349.
Hatakeyama, S. & K.I. Nakayama. 2003. U-box proteins as a new family of ubiquitin ligases. Biochem. Biophys. Res. Commun. 302: 635-645.
Hays, A.P., M. Hallet, J. Delfs, J. Morris, A. Sotrel, M.M. Shevchuk & S. DiMauro. 1981. Muscle phosphofructokinase deficiency. Abnormal polysaccharide in a case of late-onset myopathy. Neurology 31: 1077-1086.
Ianzano, L., X.C. Zhao, B.A. Minassian & S.W.Scherer. 2003. Identification of a novel protein interacting
with laforin, the EPM2A progressive myoclonus epilepsy gene product. Genomics 81: 579-587.
Ianzano, L., E.J. Young, X.C. Zhao, E.M. Chan, M.T. Rodríguez, M.V. Torrado, S.W. Scherer & B.A. Minassian 2004. Loss of function of the cytoplasmic isoform of the protein Laforin (EPM2A) causes Lafora progressive myoclonus epilepsy. Hum. Mut. 23: 170-176.
Iwaki, T., Y. Hamada & J. Tateishi. 1996. Advanced glycosylation end products and heat shock proteins acumulate in the basophilic degeneration of the myocardium and the corpora amylacea of the glia. Pathol. Int. 46: 757-763.
Ki, C.S., S.Y. Kong, D.W. Seo, S.B. Hong, H.J. Kim & J.W. Kim. 2003. Two novel mutations in the EPM2A
gene in a Korean patient with Lafora’s progressive myoclonus epilepsy. J. Hum. Genet. 48: 51-54.
Kobayashi, K., K. Iyoda, Y. Ohtsuka, S. Ohtahara & M. Yamada. 1990. Longitudinal clinocoelectrophysiologic study of a case of Lafora disease proven by skin biopsy. Epilepsia 31: 194-201.
Kufs, H. 1925. Uber eine spatform der amaurotischen idiotie und ihre heredofamiliaren grundlagen. Z. Ges. Neurol. Psychiat. 95: 169-188.
Lafora, G.R. 1911. Uber das vorkommen amyloider korperchen im innern der ganglienzellen; zugleich ein zum studium der amyloiden substanz im nervensystem. Virchows Arch [Pathol Anat ] 205: 295-303.
Lafora, G.R. & B. Gluck. 1911. Beitrag zur histopathologie der myoklonischen epilepsie. Z. Ges. Neurol.
Psychiat. 6: 1-14.
Liu, J. & D.L. Brautigan. 2000. Insulin-stimulated phosphorylation of the protein phosphatase-1 striated muscle glycogen-targeting subunit and activation of glycogen synthase. J. Biol. Chem. 275: 15940- 15947.
Lundborg, H. 1903. Die progressive myoklonus epilepsy (Unverricht’s Myoklonie). Almquist & Wiksell, Upsala. pp. 1-207.
Man, Y.H., J.W Lin., W.H. Ju, G. Ahmadian, L. Liu, L.E. Becker, M. Sheng. & Y.T. Wang. 2000. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron. 25: 649-662.
Martell, K.J., T. Angelotti & A. Ullrich. 1998. The “VH1- like” dual-specificity protein tyrosine phosphatases. Mol. Cell 8: 2-11.
Minassian, B.A., J. Sainz & A.V. Delgado-Escueta. 1996. Genetics of myoclonic and myoclonus epilepsies. 1995-96. Clin. Neurosci. 3: 223-235.
Minassian, B.A., J.R. Lee, J.A. Herbrick, J. Huizenga, S. Soder, A.J. Mungall, I. Dunham, R. Gardner, C.Y. Fong, S. Carpenter, L. Jardim, P. Satishchandra, E. Andermann, O.C. Snead, I. Lopez-Cendes, L.C. Tsui, A.V. Delgado-Escueta, G.A. Rouleau & S.W. Scherer. 1998. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20: 171-174.
Minassian, B.A., J. Sainz, J.M. Serratosa, M. Gee, L.G. Sakamoto, S. Bohlega, G. Geoffroy, C. Barr, S.W. Scherer, U. Tomiyasu, S. Carpenter, K. Wigg, A.V. Sanghvi & A.V. Delgado-Escueta. 1999. Genetic locus
heterogeneity in Lafora’s progressive myoclonus epilepsy. Ann. Neurol. 45: 262-265.
Minassian, B.A., L. Ianzano, A.V. Delgado-Escueta & S.W. Scherer. 2000a. Identification of new and commom mutations in the EPM2A gene in Lafora’s disease. Neurology 54: 488-490.
Minassian, B.A., L. Ianzano, M. Meloche, E. Andermann, G.A. Rouleau, A.V. Delgado-Escueta & S.W. Scherer. 2000b. Mutation spectrum and predicted function of Laforin in Lafora’s progressive myoclonus epilepsy. Neurology 55: 341-346.
Minassian, B.A. 2001. Lafora’s disease: Towards a clinical, pathologic, and molecular synthesis. Pediatr. Neurol. 25: 21-29.
Minassian, B.A., D.M. Andrade, L. Ianzano, E.J Young, E. Chan, C. A. Ackerkey & S.W. Scherer. 2001. Laforin is a cell membrane and endoplasmic reticulum associated protein tyrosine phosphatase. Ann. Neurol. 49: 271-275.
Minassian, B.A. 2002. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora Disease. Adv.
Neurol. 89: 199-210.
Neville, H.E., M.H. Brooke & J.H. Austin.1974. Studies in myoclonus epilepsy (Lafora body form). Arch. Neurol. 30: 466-474.
Nikaido, T., J. Austin & H. Stukenbrok. 1971. Studies in myoclonus epilepsy. III: the effects of amylolytic
enzymes on the ultrastructure of Lafora bodies. J. Histochem. Cytochem. 19: 382-385.
Nishimura, R.N., K.G. Ishak, R. Reddick, R. Porter, S. James & J.A. Barranger. 1980. Lafora disease: diagnosis by liver biopsy. Ann. Neurol. 8 : 409-415.
Powell, H.C., H.W. Ward, R.S. Garrett, M.J. Orloff & P.W. Lampert, 1979. Glycogen accumulation in the nerves and kidney of chronically diabetic rats. A quantitative electron microscopic study. J. Neuropathol. Exp. Neurol. 38: 114-127.
Raben, N., M. Danon, N. Lu, E. Lee, L. Shliselfeld, A.V. Skurat, P.J. Roach, J.C. Lawrence, O. Musumeci, S. Shanske, S. DiMauro & P. Plotz. 2001. Surprises of genetic engineering: a possible model of polyglucosan body (Lafora) disease. Neurology 56: 1739-45.
Ramón y Cajal, S., A. Blanes, A. Martínez, E. Saenz & M. Gutiérrez. 1975. Lafora’s disease: an ultrastructural and histochemical study. Acta Neuropathol (Berl.) 30: 189-196.
Roach, P.J., Y. Cao, A. Corbett, A.A. DePaoli-Roach, I. Farkas, C.J. Fiol, H. Flotow, P.R. Graves, T.A. Hardy, T.W. Hrubey, E. Viskupic & W. Zang. 1991. Glycogen metabolism and signal transduction in mammals and yeast. Adv. Enzyme Regul. 31: 101-120.
Robitaille, Y., S. Carpenter, G. Karpati & S. DiMauro. 1980. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such a Lafora’s disease and normal ageing. Brain 103: 315-336.
Roger, J., H. Gastaut, J. Boudouresques, M. Toga, D. Dubois & H. Lob. 1967. Epilepsie-myoclonic progressive avec corps de Lafora. Etude clinique et polygraphique. Contrôle anatomique ultrastructural. Rev. Neurol. (Paris) 116 : 197-212.
Roger, J., J.F. Pellissier, M. Bureau, C. Dravet, M. Revol & P. Tinuper. 1983. Le diagnostic precoce de la maladie de Lafora. Importance des manifestations paroxystiques visuelles et interet de la biopsie cutanee. Rev. Neurol. (Paris) 139: 115-124.
Roger, J., P. Genton, M. Bureau & C. Dravet. 1992. Progressive myoclonus epilepsies in childhood and adolescence. pp.381-400. In J. Roger, M. Bureau & C. Dravet (eds.). Epileptic syndromes in infancy, childhood and adolescence. Libbey. London. Sainz, J., B.A. Minassian, J.M. Serratosa, M.N. Gee, L.M.
Sakamoto, R. Iranmanesh, S. Bohlega, R.J. Baumann, S. Ryan, R.S. Sparkes & A.V. Delgado-Escueta.
Lafora progressive myoclonus epilepsy: narrowing the chromosome 6q24 locus by recombinations and homozygosities. Am. J. Hum. Genet. 61: 1205-1209.
Sakai, M., J. Austin, F. Witmer & L. Trueb. 1970. Studies in myoclonus epilepsy (Lafora body form) ; II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20: 160-176.
Schmidt, A.M., S.D. Yan, S.F. Yan & D.M. Stern. 2000. The biology of the receptor for advanced glycation
end products and its ligands. Biochim. Biophys. Acta 1498: 99-111.
Serratosa, J.M., A.V. Delgado-Escueta, I. Posada, S. Shih, I. Drury, J. Berciano, J.A. Zabala, M.C. Antunez & R.S. Sparkes. 1995. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum. Mol. Genet. 4: 1657-1663.
Serratosa, J.M., P. Gómez-Garre, M.E. Gallardo, B. Anta, D.B. de Bernabe, D. Lindhout, P.B. Augustijn, C.A. Tassinari, R.M. Malafosse , M. Topcu, D. Grid, C. Dravet, S.J. Berkovic & S.R. de Cordoba. 1999. A
novel protein tyrosine phosphatase gene is mutated in progressive epilepsy of the Lafora type (EPM2A). Hum. Mol. Genet. 8: 345-352.
Slack, F.J. & G. Ruvkun. 1998. Anovel repeat domain that is often associated with RING finger and B-box motifs. Trends Biochem. Sci. 23: 474-475.
Solís, V. 2000. Enfermedad de Lafora y efecto fundador en una pequeña localidad neotropical. Rev. Biol. Trop. 48: 703-706.
Steward, O. & G.A. Banker. 1992. Getting the message from the gene to the synapse: sorting and intracellular transport of RNA in neurons. Trends Neurosci. 15: 180-186.
Toga, M., D. Dubois & J. Hassoun. 1968. Ultra-structure des corps de Lafora. Acta Neuropathol. 10: 132-142.
Tonks, N.K. & B.G. Nell. 1996. From form to function: signaling by protein tyrosine phosphatases. Cell 87: 365-368.
Unvericht, H. 1891. Die myoclonie. pp.1-128. Franz Deuticke, Viena.
Van Heycop Ten Ham, M.W. 1974. Lafora disease, a form of progressive myoclonus epilepsy. pp 382-422. In P.J. Vinken & G.W. Bruyn (eds.). The Epilepsies. Handbook of Clinical Neurology Vol 15. North Holland Publishing Company. Amsterdam.
Villar-Palasi. C. & J. J. Guinovart. 1997. The role of glucosa- 6-phosphate in the control of glycogen synthase. FASEB J. 11: 544-558.
Wang, J, J.A Stuckey, M. J. Wishart & J.E. Dixon. 2002. A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. J. Biol. Chem. 277: 2377-2380.
Woodgett, J.R. 1994. Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin. Cancer Biol. 5: 269-275.
Yokoi, S. & J. Austin. 1968. Studies in myoclonus epilepsy (Lafora body form). Arch. Neurol. 19: 15-33.
Yokoi, S., F. Austin, F. Witmer & M. Sakai. 1968. Studies in myoclonus epilepsy (Lafora body form). 1. Isolation and preliminary characterization of Lafora bodies in two cases. Arch. Neurol. 19: 15-33.
Yokoi, S., H. Nakayama & T. Negishi. 1975. Biochemical studies on tissues from a patient with Lafora disease. Clin. Chim. Acta 62: 415-423.
Zhao, W., H. Chen, H. Xu, E. Moore, N. Meiri, M.J Quon. & D.L. Alkon. 1999. Brain insulin receptors and spatial memory: correlated changes in gene expression, tyrosine phosphorilation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 274: 34893-34902.
Comments
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2004 Revista de Biología Tropical